A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With
Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With
Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy